 Investors | Investor Relations Home | Webcast
Q4 2009 Anadys Pharmaceuticals, Inc. Earnings Conference Call (Replay)
02/24/10 at 5:00 p.m. ET |
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.
To view our latest press releases, please visit our
news page >> | | |
Receive E-mail Alerts | | Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now! |
| 2009 Annual Meeting of Stockholders Materials |
| | Date | Title | | 03/16/10 3:30 p.m. PT | | Anadys Pharmaceuticals, Inc. at ROTH OC Growth Stock Conference | | Location | Laguna Niguel, CA |
|
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
| |
|
